Back
Open Access

Addressing the confounding effect of dynamic drug therapy adherence in clinical trial design.

Session: Renal denervation (RDN) for uncontrolled hypertension: introducing the SPYRAL HTN global clinical trial program
Topic: Renal denervation
Speaker: Professor P. Blankestijn (Utrecht, NL)
Sponsored by Medtronic
Event: ESC Congress 2015

Congress Presentation

About the speaker

Professor Peter Blankestijn

Utrecht (Netherlands (The))
2 presentations
0 follower

5 more presentations in this session

Brief history of RDN.

Speaker: Professor F. Mahfoud (Homburg, DE)

Access
Slides
Thumbnail

Anatomical Optimization of renal denervation: Have we found the “sweet spot”?

Speaker: Professor F. Mahfoud (Homburg, DE)

Access
Slides
Thumbnail

Population variability: have we identified the correct population for renal denervation therapy?

Speaker: Doctor J. Davies (London, GB)

Access
Slides
Thumbnail

Blood pressure measurement: how does the decline translate to CV risk reduction?

Speaker: Professor G. Mancia (Milan, IT)

Access
Slides
Thumbnail

Introducing the SPYRAL HTN global clinical program and audience Q&A.

Speaker: Professor M. Boehm (Homburg, DE)

Access
Slides
Thumbnail

Access the full session

Renal denervation (RDN) for uncontrolled hypertension: introducing the SPYRAL HTN global clinical trial program

Speakers: Professor P. Blankestijn, Professor F. Mahfoud, Professor F. Mahfoud, Doctor J. Davies, Professor G. Mancia...
Access
Thumbnail

About the event

Image

ESC Congress 2015

29 August - 2 September 2015

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb